Tregs and allergic disease

Journal of Clinical Investigation

Volumn 114, Issue 10, 2004, Pages 1389-1397

  Robinson, Douglas S ^a,b   Larché, Mark ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CAT ALLERGEN; CD4 ANTIGEN; COLECALCIFEROL; CORTICOSTEROID; GAMMA INTERFERON; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PEPTIDE DERIVATIVE; PROTEIN FEL D 1; UNCLASSIFIED DRUG; INTERLEUKIN 2 RECEPTOR; PEPTIDE FRAGMENT;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC DISEASE; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ASTHMA; AUTOIMMUNE DISEASE; CELL FUNCTION; CYTOKINE PRODUCTION; DENDRITIC CELL; ECZEMA; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; POLLEN ALLERGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHINITIS; SENSITIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VACCINATION; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ALLERGENS; ANIMALS; ANTIGENS, CD4; ASTHMA; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ECZEMA; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-2; RHINITIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TH2 CELLS;

EID: 15244344608     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200423595     Document Type: Review

References (110)

1. Kay, A.B. 2001. Allergy and allergic diseases. N. Engl. J. Med. 344:30-37.
2. Lloyd, C.M., Gonzalo, J.A., Coyle, A.J., and Gutierrez-Ramos, J.C. 2001. Mouse models of allergic airway disease. Adv. Immunol. 77:263-295.
3. Robinson, D.S. 2000. Th-2 cytokines in allergic disease. Br. Med. Bull. 56:956-968.
4. Baecher-Allan, C., and Hafler, D.A. 2004. Suppressor T cells in human diseases. J. Exp. Med. 200:273-276.
5. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151-1164.
6. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 101:455-458.
7. Shevach, E.M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400.
8. + regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295-1302.
9. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193:1285-1294.
10. + T cells with regulatory properties from human blood. J. Exp. Med. 193:1303-1310.
11. Taams, L.S., et al. 2001. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur. J. Immunol. 31:1122-1131.
12. Ng, W.F., et al. 2001. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 98:2736-2744.
13. Stephens, L.A., Mottet, C., Mason, D., and Powrie, F. 2001. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31:1247-1254.
14. Bluestone J.A., and Abbas, A.K. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253-257.
15. Stephens, L.A., and Mason, D. 2000. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25-subpopulations. J. Immunol. 165:3105-3110.
16. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., and Weiner, H.L. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
17. Maloy, K.J., and Powrie, F. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816-822.
18. Baecher-Allan, C., Brown, J.A., Freeman, G.J., and Hafler, D.A. 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167:1245-1253.
19. Takahashi, T., et al. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303-310.
20. Read, S., Malmstrom, V., and Powrie, F. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation J. Exp. Med. 192:295-302.
21. Nakamura, K., Kitani, A., and Strober, W. 2001. Cell concact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194:629-644.
22. Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., and Sakaguchi, S. 2002. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-142.
23. McHugh, R.S., et al. 2002. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 16:311-323.
24. Piccirillo, C.A., et al. 2002. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J. Exp. Med. 196:237-246.
25. Thornton, A.M., and Shevach, E.M. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-296.
26. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
27. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
28. Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4:337-342.
29. Chen, W., et al. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 J. Exp. Med. 198:1875-1886.
30. Wildin, R.S., et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:18-20.
31. O'Garra, A., and Vieira, P. 2003. Twenty-first century Foxp3. Nat. Immunol. 4:304-306.
32. Vieira, P.L., et al. 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J. Immunol. 172:5986-5993.
33. Cohn, L., Homer, R.J., Niu, N., and Bottomly, K. 1999. T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J. Exp. Med. 190:1309-1318.
34. Szabo, S.J., et al. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 295:338-342.
35. Finotto S., et al. 2002. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 295:336-338.
36. Umetsu, D.T., Akbari, O., and Dekruyff, R.H. 2003. Regulatory T cells control the development of allergic disease and asthma. J. Allergy Clin. Immunol. 112:480-487.
37. Stassen, M., et al. 2004. Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J. Immunol. 173:267-274.
38. Curotto de Lafaille, M.A., et al. 2001. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J. Exp. Med. 194:1349-1359.
39. Suto, A., et al. 2001. Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am. J. Respir. Crit. Care Med. 164:680-687.
40. Jaffar, Z., Sivakuru, T., and Roberts, K. 2004. CD4+CD25+ T cells regulate airway eosinophilic inflammation by modulating the Th2 cell phenotype. J. Immunol. 172:3842-3849.
41. Hadeiba, H., and Locksley, R.M. 2003. Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J. Immunol. 170:5502-5510.
42. McMenamin, C., Pimm, C., McKersey, M., and Holt, P.G. 1994. Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science. 265:1869-1871.
43. Hurst, S.D., Seymour, B.W., Muchamuel, T., Kurup, V.P., and Coffman, R.L. 2001. Modulation of inhaled antigen-induced IgE tolerance by ongoing Th2 responses in the lung. J. Immunol. 166:4922-4930.
44. + T cells expressing membrane-bound TGF-β and FOXP3. J. Clin. Invest. 114:28-38. doi:10.1172/JCI200420509.
45. Cottrez, F., Hurst, S.D., Coffman, R.L., and Groux, H. 2000. T regulatory cells 1 inhibit a Th2-specific response in vivo. J. Immunol. 165:4848-4853.
46. Akbari, O., et al. 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8:1024-1032.
47. Akbari, O., DeKruyff, R.H., and Umetsu, D.T. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2:725-731.
48. Zuany-Amorim, C., et al. 2002. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 8:625-629.
49. Barrat, F.J., et al. 2002. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J. Exp. Med. 195:603-616.
50. Hoyne, G.F., Dallman, M.J., Champion, B.R., and Lamb, J.R. 2001. Notch signalling in the regulation of peripheral immunity. Immunol. Rev. 182:215-227.
51. Cosmi, L., et al. 2004. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood. 103:3117-3121.
52. Tiemessen, M.M., et al. 2002. CD4 CD25 regulatory T cells are not functionally impaired in adult patients with IgE-mediated cow's milk allergy. J. Allergy Clin. Immunol. 110:934-936.
53. Bellinghausen, I., Klostermann, B., Knop, J., and Saloga, J. 2003. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J. Allergy Clin. Immunol. 111:862-868.
54. Ling, E.M., et al. 2004. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 363:608-615.
55. Akdis, M., et al. 2004. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199:1567-1575.
56. Dieckmann, D., Bruett, C.H., Ploettner, H., Lutz, M.B., and Schuler, G. 2002. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J. Exp. Med. 196:247-253.
57. Umetsu, D.T., McIntire, J.J., Akbari, O., Macaubas, C., and DeKruyff, R.H. 2002. Asthma: an epidemic of dysregulated immunity. Nat. Immunol. 3:715-720.
58. Baldini, M., et al. 1999. A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20:976-983.
59. Eder, W., et al. 2004. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J. Allergy. Clin. Immunol. 113:482-488.
60. Eisenbarth, S.C., et al. 2002. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 196:1645-1651.
61. Pasare, C., and Medzhitov, R. 2003. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. 15:677-682.
62. Pasare, C., and Medzhitov, R. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 299:1033-1036.
63. Platts-Mills, T., Vaughan, J., Squillace, S., Woodfolk, J., and Sporik, R. 2001. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 357:752-756.
64. Karlsson, M.R., Rugtveit, J., and Brandtzaeg, P. 2004. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J. Exp. Med. 199:1679-1688.
65. Tiemessen, M.M., et al. 2004. Cow's milk-specific T-cell reactivity of children with and without persistent cow's milk allergy: key role for 1L-10. J. Allergy Clin. Immunol. 113:932-939.
66. Robinson, D.S., and Nguyen, X.D. 2004. Fluticasone propionate increases suppression of allergen-driven T cell proliferation by CD4+CD25+ T cells. J. Allergy Clin. Immunol. 114:296-301.
67. Durham, S.R., et al. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341:468-475.
68. Till, S.J., and Durham, S.R. 2004. Immunological responses to allergen immunotherapy. Clin. Allergy Immunol. 18:85-104.
69. Varney, V.A., et al. 1991. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 302:265-269.
70. Bousquet, J., et al. 1998. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81:401-405.
71. Pajno, G.B., Barberio, G., De Luca, F., Morabito, L., and Parmiani, S. 2001. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy. 31:1392-1397.
72. Moller, C., et al. 2002. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109:251-256.
73. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98:1676-1683.
74. Till, S., et al. 1997. IL-5 production by allergen-stimulated T-cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin. Exp. Immunol. 110:114-121.
75. Wachholz, P., et al. 2002. Grass pollen immunotherapy for hayfever is associated with increases in local nasal mucosal but not peripheral Th1/Th2 ratios. Immunology. 105:56-62.
76. Ebner, C., et al. 1997. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy. 27:1007-1015.
77. Jutel, M., et al. 1995. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T-cell cultures. J. Immunol. 154:4187-4194.
78. Francis, J.N., Till, S.J., and Durham, S.R. 2003. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111:1255-1261.
79. Bellinghausen, I., et al. 1997. Insect venom immunotherapy induces interleukin-10 production and a Th2- to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27:1131-1139.
80. Jutel, M., et al. 2003. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33:1205-1214.
81. Varney, V.A., et al. 1993. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92:644-651.
82. Durham, S.R., et al. 1996. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 97:1356-1365.
83. Wilson, D.R., et al. 2001. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin. Exp. Allergy. 31:1705-1713.
84. Nouri-Aria, K., et al. 2004. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172:3252-3259.
85. Daeron, M., et al. 1995. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity. 3:635-646.
86. Malbec, O., et al. 1998. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J. Immunol. 160:1647-1658.
87. Zhu, D., Kepley, C.L., Zhang, M., Zhang, K., and Saxon, A. 2002. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 8:518-521.
88. Wachholz, P.A., Soni, N.K., Till, S.J., and Durham, S.R. 2003. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol. 112:915-922.
89. Van Neerven, R.J., et al. 1999. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163:2944-2952.
90. Norman, P.S., Lichtenstein, L.M., and Marsh, D.G. 1981. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J. Allergy Clin. Immunol. 68:460-470.
91. Pauli, G., et al. 2000. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin. Exp. Allergy. 30:1076-1084.
92. Tighe, H., et al. 2000. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:124-134.
93. Rachmilewitz, D., et al. 2004. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 126:520-528.
94. Gaur, A., Wiers, B., Liu, A., Rothbard, J., and Fathman, C.G. 1992. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 258:1491-1494.
95. Clayton, J.P., et al. 1989. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J. Exp. Med. 169:1681-1691.
96. Daniel, D., and Wegmann, D.R. 1996. Protection of non-obese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. U. S. A. 93:956-960.
97. Metzler, B., and Wraith, D.C. 1993. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5:1159-1165.
98. Burkhart, C., Liu, G.Y., Anderton, S.M., Metzler, B., and Wraith, D.C. 1999. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. 11:1625-1634.
99. Prakken, B.J., et al. 1997. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc. Natl. Acad. Sci. U. S. A. 94:3284-3289.
100. Hoyne, G.F., O'Hehir, R.E., Wraith, D.C., Thomas, W.R., and Lamb, J.R. 1993. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice J. Exp. Med. 178:1783-1788.
101. Sundstedt, A., O'Neill, E.J., Nicolson, K.S., and Wraith, D.C. 2003. Role for 1L-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170:1240-1248.
102. Prakken, B.J., et al. 2004. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arrhritis. Proc. Natl. Acad. Sci. U. S. A. 101:4228-4233.
103. Haselden, B.M., Kay, A.B., and Larche, M. 1999. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189:1885-1894.
104. Ali, F.R., Oldfield, W.L., Higashi, N., Larche, M., and Kay, A.B. 2004. Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am. J. Respir. Crit. Care Med. 169:20-26.
105. Oldfield, W.L., Larche, M., and Kay, A.B. 2002. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 360:47-53.
106. Oldfield, W.L., Kay, A.B., and Larche, M. 2001. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167:1734-1739.
107. Muller, U., et al. 1998. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101:747-754.
108. Verhoef, A., Alexander, C., Kay, A.B., and Larché, M. 2004. Allergen-based peptide immunotherapy is associated with functional modifications in allergen-specific T-cell subpopulations [abstract]. J. Allergy Clin. Immunol. 113(Suppl.):918.
109. + T cells. Allergy. 59:1097-1101.
110. Alexander, C., Ying, S., Kay, A.B., and Larché, M. 2004. Fel d 1-derived T cell peptide therapy induces recruitment of activated (CD4+CD25+;CD4+IFN-gamma+) Th1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy. In press.